bioAffinity Technologies, Inc.
BIAF BIAFWCIK 0001712762 · Services-Commercial Physical & Biological Research · Nasdaq, Nasdaq
- bioAffinity Technologies, Inc. (until 2026-06-18)
Revenue (TTM)
$5.92M
−34.2% YoY
Q1 May 2026
Net Income (TTM)
−$15.4M
−64.9% YoY
Q1 May 2026
EPS Diluted (TTM)
−$10.52
+61.5% YoY
Q1 May 2026
Gross Margin
4.1%
Q1 May 2026
Operating Margin
-186.7%
Q1 May 2026
Net Margin
-260.2%
Q1 May 2026
Free Cash Flow (TTM)
−$8.87M
Q1 May 2026
Cash
$3.1M
Q1 May 2026
Total Debt
$260K
Q1 May 2026
Shares Outstanding
4.53M sh
Q1 May 2026
Revenue & Net Income
EPS (Diluted)
Margins
Cash Flow
Revenue Growth (YoY)
Balance Sheet
Cash vs Debt
Latest news
All news →-
High Neutral
bioAffinity Technologies (BIAF) Enters $3.2M Stock Purchase Agreement
bioAffinity Technologies is selling shares and pre-funded warrants to raise up to $3.2 million at $0.80 per share.